XNAS
JBIO
Market cap861mUSD
Oct 08, Last price
14.15USD
1D
2.76%
1Q
-32.46%
IPO
-27.10%
Name
Jade Biosciences Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
16.96%
Shrs. gr., 5y
114.08%
Rev. gr., 5y
%
Revenues
0
Net income
-127m
L+82.99%
CFO
-95m
L+33.00%
Dividend
Apr 29, 20252.4 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Key people
Independent Chairman of the Board · since 2024
Timothy Noyes
Chief Executive Officer, Director · since 2021
Benjamin Dake
President, Chief Operating Officer, Secretary · since 2021
Stephen Yu
Senior Vice President - Quality · since 2022
Marinus Verwijs
Chief Technical Officer · since 2023
Ralph Niven
Chief Scientific Officer · since 2022
Bradford Dahms
Chief Financial Officer, Treasurer · since 2025
Donna Dea
Head of Regulatory Affairs · since 2020
Hunter Gillies
Chief Medical Officer · since 2020
Independent Director · since 2021
Independent Director · since 2020
Mark Iwicki
Independent Director · since 2024
Joshua Resnick
Independent Director · since 2020
Donald Santel
Independent Director · since 2023
Valuation
Title in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT |